OR WAIT null SECS
July 27, 2023
Janssen has received a positive opinion from the EMA for two novel bispecific antibodies, TALVEY (talquetamab) and TECVAYLI (teclistamab), which the company is developing to treat blood cancer.
July 11, 2023
In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.
June 01, 2023
A partnership between Rentschler Biopharma and Ikarovec will support the accelerated development of novel gene therapies for the treatment of eye diseases.
May 03, 2023
The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.
E&L analytical testing methods can be determined through pointed consideration of the differences small- and large-molecule drug products.
May 02, 2023
In this episode, Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.
April 03, 2023
Despite the advantages intensified processes can offer developers, there are still some obstacles to overcome before broader application of new technologies will be implemented.
April 02, 2023
Alternative approaches to freeze-drying are gaining popularity and will help to overcome some of the challenges associated with conventional lyophilization.
Considering the differences between small- and large-molecule drug products can help determine analytical testing methods for E&L.
March 30, 2023
Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.